Teva Launches Generic Version of Aloxi in US
28 March 2018 - - Petach Tikva, Israel-based generic and specialty medicines company Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has launched a generic version of Aloxi (palonosetron HCI) injection, 0.25 mg/5 mL, in the US, the company said.
Palonosetron hydrochloride injection, an 5-HT3 receptor antagonist, is used in adults to prevent nausea and vomiting that may occur as a result of receiving cancer chemotherapy with a moderate or high risk of causing nausea and vomiting.
It is also given to prevent nausea and vomiting up to 24 hours after surgery.
Teva is a patient-centric healthcare solutions, and generic and specialty medicines producer. It leverages its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area.
In specialty medicines, the company has an innovative treatment for multiple sclerosis as well as late-stage development programs for other disorders of the central nervous system, including movement disorders, migraine, pain and neurodegenerative conditions, as well as a broad portfolio of respiratory products.